For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

The Department of Health and Human Services’ mRNA pullback only applies to their use in upper respiratory disease, according ...

The move comes after Robert F. Kennedy Jr. received pressure from the Children’s Health Defense, an anti-vaccine non-profit ...

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be ...

BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Gray Delany's ouster comes days after Health Secretary Robert F. Kennedy Jr. controversially axed 22 mRNA vaccine contracts ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic ...